Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation

Waylan K. Bessler, Grace Kim, Farlyn Z. Hudson, Julie A. Mund, Raghuveer Mali, Keshav Menon, Reuben Kapur, D. Clapp, David Ingram, Brian K. Stansfield

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21Ras, and increases Ras signaling. Heterozygous Nf1 (Nf1+/-) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly, lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1+/- mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1+/- mice. MCP-1 induces a dose-responsive increase in Nf1+/- macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1+/- SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1+/- neointima formation, we induced neointima formation by carotid artery ligation in Nf1+/- and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively inhibited Nf1+/- neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1+/- neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1+/- monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.

Original languageEnglish (US)
Article numberddv635
Pages (from-to)1129-1139
Number of pages11
JournalHuman Molecular Genetics
Volume25
Issue number6
DOIs
StatePublished - Aug 17 2015

Fingerprint

Neointima
Chemokine CCL2
Neurofibromatosis 1
Monocytes
Macrophages
Smooth Muscle Myocytes
Pathologic Constriction
Neurofibromatosis 1 Genes
Neurofibromin 1
CCR2 Receptors
Carotid Arteries
Chemokines
Ligation
Phosphotransferases
Alleles
Ligands
Phenotype
Mutation

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Bessler, W. K., Kim, G., Hudson, F. Z., Mund, J. A., Mali, R., Menon, K., ... Stansfield, B. K. (2015). Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. Human Molecular Genetics, 25(6), 1129-1139. [ddv635]. https://doi.org/10.1093/hmg/ddv635

Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. / Bessler, Waylan K.; Kim, Grace; Hudson, Farlyn Z.; Mund, Julie A.; Mali, Raghuveer; Menon, Keshav; Kapur, Reuben; Clapp, D.; Ingram, David; Stansfield, Brian K.

In: Human Molecular Genetics, Vol. 25, No. 6, ddv635, 17.08.2015, p. 1129-1139.

Research output: Contribution to journalArticle

Bessler, WK, Kim, G, Hudson, FZ, Mund, JA, Mali, R, Menon, K, Kapur, R, Clapp, D, Ingram, D & Stansfield, BK 2015, 'Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation', Human Molecular Genetics, vol. 25, no. 6, ddv635, pp. 1129-1139. https://doi.org/10.1093/hmg/ddv635
Bessler WK, Kim G, Hudson FZ, Mund JA, Mali R, Menon K et al. Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. Human Molecular Genetics. 2015 Aug 17;25(6):1129-1139. ddv635. https://doi.org/10.1093/hmg/ddv635
Bessler, Waylan K. ; Kim, Grace ; Hudson, Farlyn Z. ; Mund, Julie A. ; Mali, Raghuveer ; Menon, Keshav ; Kapur, Reuben ; Clapp, D. ; Ingram, David ; Stansfield, Brian K. / Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. In: Human Molecular Genetics. 2015 ; Vol. 25, No. 6. pp. 1129-1139.
@article{9ef54985eb4046fca35a1cd51d8cfc3d,
title = "Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation",
abstract = "Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21Ras, and increases Ras signaling. Heterozygous Nf1 (Nf1+/-) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly, lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1+/- mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1+/- mice. MCP-1 induces a dose-responsive increase in Nf1+/- macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1+/- SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1+/- neointima formation, we induced neointima formation by carotid artery ligation in Nf1+/- and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively inhibited Nf1+/- neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1+/- neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1+/- monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.",
author = "Bessler, {Waylan K.} and Grace Kim and Hudson, {Farlyn Z.} and Mund, {Julie A.} and Raghuveer Mali and Keshav Menon and Reuben Kapur and D. Clapp and David Ingram and Stansfield, {Brian K.}",
year = "2015",
month = "8",
day = "17",
doi = "10.1093/hmg/ddv635",
language = "English (US)",
volume = "25",
pages = "1129--1139",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation

AU - Bessler, Waylan K.

AU - Kim, Grace

AU - Hudson, Farlyn Z.

AU - Mund, Julie A.

AU - Mali, Raghuveer

AU - Menon, Keshav

AU - Kapur, Reuben

AU - Clapp, D.

AU - Ingram, David

AU - Stansfield, Brian K.

PY - 2015/8/17

Y1 - 2015/8/17

N2 - Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21Ras, and increases Ras signaling. Heterozygous Nf1 (Nf1+/-) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly, lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1+/- mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1+/- mice. MCP-1 induces a dose-responsive increase in Nf1+/- macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1+/- SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1+/- neointima formation, we induced neointima formation by carotid artery ligation in Nf1+/- and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively inhibited Nf1+/- neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1+/- neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1+/- monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.

AB - Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21Ras, and increases Ras signaling. Heterozygous Nf1 (Nf1+/-) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly, lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1+/- mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1+/- mice. MCP-1 induces a dose-responsive increase in Nf1+/- macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1+/- SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1+/- neointima formation, we induced neointima formation by carotid artery ligation in Nf1+/- and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively inhibited Nf1+/- neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1+/- neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1+/- monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.

UR - http://www.scopus.com/inward/record.url?scp=84960124044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960124044&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddv635

DO - 10.1093/hmg/ddv635

M3 - Article

C2 - 26740548

AN - SCOPUS:84960124044

VL - 25

SP - 1129

EP - 1139

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 6

M1 - ddv635

ER -